Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMSB301 in Type 1 Interferonopathies
NCT07364513Phase 1Recruiting
- Sponsor
- ImmuneSensor Therapeutics
- Start
- Jan 2026
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IMSB301 in Aicardi-Goutières syndrome (AGS), systemic lupus erythematosus (SLE), Familial chilblain lupus and 1 more, sponsored by ImmuneSensor Therapeutics. Primary endpoint: Drug-related safety at 57 days. Started Jan 2026; status: recruiting.
02
Drugs
IMSB301
03
Conditions
Aicardi-Goutières syndrome (AGS)systemic lupus erythematosus (SLE)Familial chilblain lupustype 1 interferonopathy
Beyond the preview
Go deeper on NCT07364513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07364513.